New York, May 22, 2026, 04:20 (EDT)
- Lumexa Imaging finished Thursday at $8.18, a gain of 10.5%. The stock was quoted at $8.53 after the bell.
- Director Brett Brodnax bought 35,000 shares at $7.25 apiece, according to an SEC filing from May 21.
- Barclays lowered its Lumexa target to $9 from $15. The bank said RadNet is beating Lumexa on advanced volume gains and price growth.
Lumexa Imaging Holdings shares moved higher late after a director picked up shares in the open market. The new buying gave investors an inside read on the outpatient imaging company, which has slid sharply since its IPO.
The stock finished Thursday at $8.18, a gain of 10.5%. After the bell, it was at $8.53, according to Google Finance. Shares are still trading sharply under the $18.50 IPO price set in December.
The timing stands out: the buy happened right ahead of a long U.S. holiday weekend and followed a target cut on Wall Street. U.S. equity markets will run regular hours Friday, then close on Monday, May 25, for Memorial Day, Nasdaq’s 2026 holiday calendar shows.
Brett Brodnax reported buying 35,000 Lumexa shares at $7.25 apiece on May 19, according to a Form 4 filing. His direct stake rises to 62,027 shares. The filing is dated May 21.
Director Henry Lee Cooper also bought shares recently, according to a separate SEC filing. The Cooper Family Trust picked up 30,000 shares on May 14 at a weighted average of $7.4371 a share.
Barclays cut its price target on Lumexa to $9 from $15 but kept an Overweight. The bank said RadNet, another diagnostics name, has stronger gains in advanced volume and pricing for imaging services. The tape remains mixed.
Lumexa posted a 3.1% bump in revenue to $252.5 million in the first quarter, with net income coming in at $1.7 million. Adjusted EBITDA was $51.2 million. The company is based in Raleigh, North Carolina.
Lumexa CEO Caitlin Zulla said in the release the company “continued to drive strong growth in same-center advanced imaging volumes.” Zulla added that new centers were “ramping according to our plans.” The company defines advanced procedures as MRI and CT scans. Lumexa Imaging, Inc.
Lumexa Imaging, Inc. stuck to its 2026 forecast, with revenue seen at $1.045 billion to $1.097 billion. Adjusted EBITDA is expected in a range of $234 million to $242 million, and adjusted EPS at 71 cents to 77 cents. The company said the EBITDA view factors in about $7 million of extra public-company costs versus 2025.
Lumexa has traded publicly for under six months. The company, backed by Welsh, Carson, Anderson & Stowe, brought in $462.5 million at its IPO. At its Nasdaq launch it ran 184 centers in 13 states, according to Reuters in December.
Director buying isn’t a full answer for the stock. Lumexa’s scan growth or pricing may still trail RadNet, and higher public-company costs and debt could eat into margins—so gains may not last. As of March 31, the company showed about $817 million in long-term debt. Cash and equivalents were $51.2 million.
